Catalog No.: PC-20781Not For Human Use, Lab Use Only.
Mubritinib (TAK-165) is a potent inhibitor of human epidermal growth factor receptor 2 (HER2, ERBB2) tyrosine kinase with IC50 of 6 nM, also is a potent Complex I inhibitor with IC50 of 51 nM.
Mubritinib (TAK-165) is a potent inhibitor of human epidermal growth factor receptor 2 (HER2, ERBB2) tyrosine kinase with IC50 of 6 nM, also is a potent Complex I inhibitor with IC50 of 51 nM.
Mubritinib (TAK-165) does not inhibit other types tyrosine kinase up to 25,000 nM.
Mubritinib (TAK-165) inhibits HER2 phosphorylation and its down-stream Akt and MAPK in HER2 strongly expressing cells (BT474 breast cancer cell line).
Mubritinib (TAK-165) shows synergistic effect with trametinib in KRAS-mutant cell lines.
Mubritinib exhibits strong anti-leukemic effects in vitro and in vivo, functions through ubiquinone-dependent inhibition of electron transport chain (ETC) complex I activity.
Mubritinib (TAK-165) inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
